Viracta Therapeutics, Inc. (VIRX)
OTCMKTS · Delayed Price · Currency is USD
0.0098
+0.0002 (1.88%)
Inactive · Last trade price on Jul 16, 2025

Viracta Therapeutics Company Description

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.

The company’s lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.

It’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

The company’s product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate.

The company is headquartered in Cardiff, California.

Viracta Therapeutics, Inc.
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees40
CEOCraig Jalbert

Contact Details

Address:
2533 South Coast Highway 101
Cardiff, Delaware 92007
United States
Phone858 400 8470
Websiteviracta.com

Stock Details

Ticker SymbolVIRX
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS92765F1084
SIC Code2836

Key Executives

NamePosition
Craig R. Jalbert CIRAChief Executive Officer, President, Chief Financial Officer, Treasurer, Corporate Secretary and Director